The drugmaker and its partner, Germany’s BioNTech, say they expect to request emergency use authorization of their vaccine in children ages 5 to 11 “in the coming weeks.” The companies also plan to submit data to the European Medicines Agency and other regulators.

The two-shot Pfizer vaccine is currently available for those 12 and older. An estimated 100 million people in the U.S. have been fully vaccinated with it, according to the Centers for Disease Control and Prevention.

Pfizer tested a lower dose of the shots in children. The drugmaker said last week that researchers found the vaccine developed coronavirus-fighting antibody levels in children that were just as strong as those found in teenagers and young adults getting regular-strength doses.

Earlier this month, FDA chief Dr. Peter Marks told the AP that once Pfizer turns over its study results, his agency would evaluate the data “hopefully in a matter of weeks” to decide if the shots are safe and effective enough for younger kids.

Another U.S. vaccine maker, Moderna, also is studying its shots in elementary school-aged children. Results are expected later in the year.

More health care and Big Pharma coverage from Fortune:

• Health insurers justify passing COVID treatment costs on to patients despite massive profits
• Why pregnant people are now eligible for COVID-19 vaccine boosters
• Portugal leads the world in COVID-19 vaccinations
• A WHO-approved Novavax vaccine could upstage mRNA jabs—if it can solve its manufacturing delays
• Duckworth, Raimondo: Congress must back the president’s historic investment in home care workers